@article{818a49a628014a75a593a972c34786ae,
title = "The Severe Typhoid Fever in Africa Program Highlights the Need for Broad Deployment of Typhoid Conjugate Vaccines",
abstract = "The Typhoid Surveillance in Africa Program (TSAP) and the Severe Typhoid Fever in Africa (SETA) program have refined our understanding of age and geographic distribution of typhoid fever and other invasive salmonelloses in Africa and will help inform future typhoid control strategies, namely, introduction of typhoid conjugate vaccines.",
keywords = "enteric fever, surveillance, typhoid conjugate vaccine, typhoid fever, vaccine introduction",
author = "Carey, {Megan E.} and Steele, {A. Duncan}",
note = "Funding Information: Financial support. This research was funded by the Bill & Melinda Gates Foundation [OPP1127988]. The International Vaccine Institute acknowledges its donors including the Republic of Korea and the Swedish International Development Cooperation Agency. This publication was made possible through a grant from the Bill & Melinda Gates Foundation [OPP1201031]. Funding Information: The high disease burden observed, coupled with the availability of a WHO Prequalified TCV and Gavi support, mean that there is massive potential impact of TCV introduction. Important TCV performance data are being generated by the Typhoid Vaccine Acceleration Consortium (TyVAC), which is conducting large-scale efficacy studies in Nepal, Malawi, and Bangladesh [16]. Additional interventions using Bharat Biotech{\textquoteright}s Typbar-TCV are ongoing in Navi Mumbai, India, where the municiple government requested vaccine intervention [17] and in Pakistan in response to the ongoing outbreak of extensively drug-resistant (XDR) Salmonella enterica serovar Typhi. Additional large-scale vaccine studies will launch in 2020 in two African countries, Ghana and the DRC, under the coordination of the University of Cambridge and International Vaccine Institute, with funding from the European and Developing Countries Clinical Trials Partnership and the Bill & Melinda Gates Foundation. Importantly, there is a strong pipe-line of new TCV candidates, with three additional manufacturers conducting late-stage clinical trials, which will contribute to increased supply security and price competition [18]. Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.",
year = "2019",
month = oct,
day = "30",
doi = "10.1093/cid/ciz637",
language = "English",
volume = "69",
pages = "S413--S416",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
}